[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-021026013--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-021026013","PRESSRELEASE"," 19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1\u002FGIP Agonist, Presented at EASD","2026-10-02T06:01:25.000+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> MILAN, Oct. 2, 2026 \u002FPRNewswire\u002F -- From September 28 to October 2, 2026, the Annual Meeting of the European Association for the Study of Diabetes (EASD) is being held in Milan, Italy. Hansoh Pharma's self-developed dual-biased glucagon-like peptide-1\u002Fglucose-dependent insulinotropic polypeptide (GLP-1\u002FGIP) receptor agonist, Olatorepatide (HS-20094), was presented as a Late-breaking Abstract (LBA) oral presentation, reporting the results from the Chinese Phase Ⅲ weight management study (LIGHTEN).\u003C\u002Fp>\u003Cp> The findings show that Olatorepatide exhibits substantial weight‑loss efficacy and favorable gastrointestinal tolerability: Weight-loss Efficacy: Mean weight loss of 19.3% was achieved at Week 48 in the olatorepatide 15 mg group, with no weight-loss plateau observed; Waist-circumference Reduction: Mean waist-circumference reduction of 16.0 cm was observed in the olatorepatide 15 mg group; Low Incidence of Gastrointestinal Adverse Events: Nausea 7.8%; vomiting 4.9%. 1\u003C\u002Fp>\u003Cp> LIGHTEN is a multicenter, randomized, double-blind, placebo-controlled Phase III study conducted in Chinese adults with overweight or obesity, enrolling a total of 604 participants. Eligible participants had a BMI (Body Mass Index) ≥28kg\u002Fm², or a BMI of 24–28kg\u002Fm² accompanied by at least one weight-related comorbidity. Participants were randomized 1:1:1:1 to receive once-weekly subcutaneous injections of Olatorepatide 5mg, 10mg, 15mg, or placebo for 48 weeks. The co-primary endpoints were the percentage change in body weight from baseline at 48 weeks and the proportion of participants achieving ≥ 5% weight loss. Overall, 90.1% of participants completed the full 48-week treatment period.\u003C\u002Fp>\u003Cp> Study results showed that under the efficacy estimand, mean body weight reductions at week 48 were −12.5%, −17.5% and −19.3% in the Olatorepatide 5 mg, 10 mg and 15 mg groups, respectively, versus −2.7% in the placebo group. Under the treatment-regimen estimand, mean body weight reductions were −11.8%, −17.0% and −18.7% across the three Olatorepatide dose groups, respectively, versus -2.5% in the placebo group. All between-group differences were statistically significant (P \u003C 0.0001).\u003C\u002Fp>\u003Cp> In terms of weight loss goal achievement rates, under the efficacy estimand, the proportions for the Olatorepatide 5mg, 10mg, 15mg and placebo groups were as follows:≥5% weight loss: 87.3%, 97.2%, 95.2% and 28.6%;≥10% weight loss: 61.7%, 89.3%, 88.9% and 14.6%;≥15% weight loss: 32.6%, 60.2%, 71.7% and 3.2%.\u003C\u002Fp>\u003Cp> Notably, the weight loss curve showed a continued downward trend at Week 48, without reaching a plateau, suggesting that a longer treatment duration may yield further weight-loss benefits.\u003C\u002Fp>\u003Cp> Under the efficacy estimand, mean reductions in waist circumference from baseline were 10.5cm, 14.4cm, and 16.0cm in the Olatorepatide 5mg, 10mg and 15mg groups, respectively, versus 3.6cm in the placebo group, with statistically significant differences (P \u003C 0.0001).\u003C\u002Fp>\u003Cp> In addition, Olatorepatide brought improvements in metabolic parameters including blood pressure, lipid profiles, glycated hemoglobin (HbA1c), homeostatic model assessment for insulin resistance (HOMA‑IR), urine albumin-to-creatinine ratio (UACR) and uric acid, demonstrating comprehensive metabolic benefits.\u003C\u002Fp>\u003Cp> The overall safety profile of Olatorepatide was similar to that of incretin-based therapies approved for weight management. Its incidence of gastrointestinal adverse events was notably lower than published data for currently available agents of the same class. The mean incidence of nausea, vomiting, diarrhea, and constipation in the Olatorepatide treatment groups was 7.8%, 4.9%, 16.9%, and 5.1%, respectively, versus 2.6%, 2.0%, 7.8%, and 1.3% in the placebo group. No participants discontinued treatment or withdrew early due to Olatorepatide treatment-related adverse events.\u003C\u002Fp>\u003Cp> A dual-biased GLP-1\u002FGIP receptor agonist, Olatorepatide offers a novel signaling pathway approach to overcoming the challenge of achieving both weight loss efficacy and tolerability. This Phase III weight-management study conducted in Chinese adults with overweight or obesity demonstrated significant weight loss efficacy along with favorable safety and tolerability, supporting its potential as a novel weight management therapy.\u003C\u002Fp>\u003Cp> The EASD Annual Meeting is one of the most influential academic conferences in the global diabetes and metabolism field. The LBA sessions are dedicated to the latest research of high innovation and major scientific significance. The selection of the Phase III study of Olatorepatide for this LBA oral presentation reflects international peers' high recognition of its data quality and clinical value.\u003C\u002Fp>\u003Cp> Olatorepatide Injection is a once-weekly subcutaneous dual-biased GLP‑1\u002FGIP receptor agonist. It functions by modulating metabolic pathways governing appetite regulation, glucose metabolism, and energy balance. Olatorepatide is also currently in Phase III clinical development in China for the treatment of type 2 diabetes mellitus. In June 2025, Hansoh Pharmaceutical entered into a strategic collaboration with Regeneron, granting Regeneron exclusive overseas development and commercialization rights for the asset. In June 2026, the New Drug Application (NDA) for Olatorepatide Injection for long-term weight management in adults with overweight or obesity was accepted for review by the National Medical Products Administration (NMPA) of China.\u003C\u002Fp>\u003Cp> Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with the mission of \"Continuous innovation for better life\". The Company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (\"CNS\") and anti-infectives.\u003C\u002Fp>\u003Cp> References[1] L. Ji, et al. Efficacy and safety of olatorepatide, a novel dual-biased GLP-1\u002FGIP receptor agonist in Chinese adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 3 study.LBA 27.EASD 2026.\u003C\u002Fp>\u003Cp> View original content:https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002F19-3-weight-loss-at-week-48-phase--data-of-olatorepatide-hansohs-dualbiased-glp1gip-agonist-presented-at-easd-302896912.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","MILAN, Oct. 2, 2026 \u002FPRNewswire\u002F -- From September 28 to October 2, 2026, the Annual Meeting of the European Association for the Study of Diabetes (EASD) is bei",[16,21,25,26,31,36,41,46,51,56],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-021026024"," Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs","2026-10-02T08:01:25.000+02:00","The acquisition is Samfara's first investment and is backed by a syndicate of European and North American institutional investors and family offices LONDON, Oct",{"id":22,"title":23,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":24},"CSN-021026023"," MIMARU Opens Osaka Namba Property with Six-person Apartments and Sky Garden Suite","TOKYO, Oct. 2, 2026 \u002FPRNewswire\u002F -- MIMARU, Japan's leading apartment hotel brand for families and groups, operated by Cosmos Hotel Management Co., Ltd., opened",{"id":4,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":11,"orgId":13,"description":14},{"id":27,"title":28,"pubDate":29,"logoUrl":8,"thirdParty":11,"orgId":13,"description":30},"CSN-021026008"," Angel Aligner Upgrades Torque Ridges to \"Pressure Points\" in Europe","2026-10-02T04:04:25.000+02:00","New Feature Improves Torque Control by Leveraging Pressure Points and Trimline Options SAN CLEMENTE, Calif., Oct. 2, 2026 \u002FPRNewswire\u002F -- Angelalign Technology ",{"id":32,"title":33,"pubDate":34,"logoUrl":8,"thirdParty":11,"orgId":13,"description":35},"CSN-021026006"," Singcore Unveils S1 Pro: an All-in-One AI Karaoke System Launching on Kickstarter in October 2026","2026-10-02T03:04:25.000+02:00","RANCHO CUCAMONGA, Calif., Oct. 2, 2026 \u002FPRNewswire\u002F -- Singcore, an AI singing entertainment brand, announces the upcoming launch of its all-in-one AI karaoke s",{"id":37,"title":38,"pubDate":39,"logoUrl":8,"thirdParty":11,"orgId":13,"description":40},"CSN-011026223"," CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell Therapies","2026-10-01T23:10:25.000+02:00","FORT COLLINS, Colo., Oct. 1, 2026 \u002FPRNewswire\u002F -- CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awa",{"id":42,"title":43,"pubDate":44,"logoUrl":8,"thirdParty":11,"orgId":13,"description":45},"CSN-011026213"," Mews launches Guest Messaging and Automations: GMs set the workflow, front desk staff get back to hosting","2026-10-01T22:33:24.000+02:00","Guest Messaging delivers informed answers to guests while giving hotel teams a single, AI-powered inbox. Automations let hotel teams build the loyalty moments f",{"id":47,"title":48,"pubDate":49,"logoUrl":8,"thirdParty":11,"orgId":13,"description":50},"CSN-011026208"," OSCP rondt door New Science Ventures geleide Series A-financiering af","2026-10-01T21:47:25.000+02:00","De financiering zal worden gebruikt om de productie van OSCP's ITAR-vrije fotonische IMU's in Montréal op te schalen naarmate de vraag naar navigatie die ook we",{"id":52,"title":53,"pubDate":54,"logoUrl":8,"thirdParty":11,"orgId":13,"description":55},"CSN-011026200"," Ditto Named a Product Leader in KuppingerCole Analysts Leadership Compass for Identity Verification","2026-10-01T20:42:25.000+02:00","KuppingerCole Analysts highlights Ditto's binding of verified identity to high-assurance authentication, and its no-code orchestration layer BARCELONA, Oct. 1, ",{"id":57,"title":58,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":60},"CSN-011026199"," Petrus Advisers & Petrus Legal Strategies (\"Petrus\") on SNP Schneider-Neureither & Partner SE","2026-10-01T20:41:25.000+02:00","ST. HELIER, Jersey and LONDON, Oct. 1, 2026 \u002FPRNewswire\u002F -- Petrus has noted the press and sell-side coverage of SNP over recent months, in particular the expec"]